EMQN CIC is pleased to announce the launch of a new EQA scheme for CYP2C19 Point-of-Care Testing (POCT), suitable for use with the NICE-recommended Genedrive® CYP2C19 ID Kit.
CYP2C19 Point-of-Care Pharmacogenomic EQA Scheme EMQN CIC’s CYP2C19 EQA scheme is designed to support the accurate and timely identification of CYP2C19 variants in acute clinical settings. This ensures that patients—particularly those presenting with recent ischaemic stroke or transient ischaemic attack (TIA)—receive the most appropriate antiplatelet therapy. Identifying CYP2C19 poor or intermediate metabolisers enables tailored clopidogrel prescribing, which may improve clinical […]
EMQN launches new EQA scheme for MT-RNR1 POCT for use with the Genedrive® MT-RNR1 ID Kit
EMQN CIC is pleased to announce the launch of a new EQA scheme for MT-RNR1 Point-of-Care Testing (POCT), suitable for use with the NICE-approved Genedrive® MT-RNR1 ID Kit. This scheme is designed to support the accurate identification of patients in acute clinical settings who carry the MT-RNR1 m.1555A>G variant, ensuring they receive alternative antibiotics to prevent hearing loss. This […]
EMQN to introduce innovative EQA Scheme for MT-RNR1 POCT
As the healthcare landscape has begun to rely increasingly on the use of point-of-care testing at, or close to, the patient’s bedside, it is crucial to ensure those tests are accurate and reliable, since immediate clinical decisions are based on the outcomes where even the slightest error could have profound consequences. EMQN CIC has introduced […]